Figure 2

Developmental changes in circulating FGF19 and FGF21 in human infants. AGA, appropriate-for-gestational-age; SGA, small-for-gestational-age. Values are mean±s.e.m. In AGA newborns, FGF19 levels were assessed at birth (day 0; n=14); at day 2 (≈35 h of life; n=11); at 4 months (n=15); and at 12 months (n=11). FGF21 levels were assessed at birth (day 0; n=21); at day 2 (≈35 h of life; n=11); at 4 months (n=20); and at 12 months (n=17). In SGA newborns, FGF19 levels were assessed at birth (day 0; n=14) and at 4 months (n=14). FGF21 levels were assessed at birth (day 0; n=21) and at 4 months (n=19). The line and dashed bars are the mean±s.e.m. of adult levels (n=35; see text for details). (a) Serum FGF19 and FGF21 levels in AGA infants from birth to age 12 months. For FGF19, *P=0.0001 (0 vs 4 months and 0 vs 12 months); ^†P=0.005 (4 vs 12 months); ^#P=0.0001 (0, 2 days and 4 months vs adults). For FGF21, *P=0.0001 (0 vs 2 days); **P=0.0003 (0 vs 4 months); ***P=0.009 (0 vs 12 months); ^#P=0.02 (0 vs adults); ^##P=0.008 (4 months vs adults); ^###P=0.01 (12 months vs adults). (b) Serum FGF19 and FGF21 levels in AGA (black circles) and SGA infants (white circles) at birth and at the age of 4 months. For FGF19, ^#P=0.0001 (0 vs 4 in the AGA subgroup); ^†P=0.0001(0 vs 4 months in the SGA subgroup); *P=0.0001 (AGA vs SGA at 4 months). For FGF21, ^#P=0.0001 (0 vs 4 in the AGA subgroup); ^†P=0.0001(0 vs 4 in the SGA subgroup).